

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 2 | 2 | 1 | — | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Spondylarthritis | D025241 | — | — | 1 | — | — | — | — | 1 |
| Spondylitis | D013166 | — | M46.9 | 1 | — | — | — | — | 1 |
| Axial spondyloarthritis | D000089183 | — | — | 1 | — | — | — | — | 1 |
| Drug common name | Vunakizumab |
| INN | vunakizumab |
| Description | Vunakizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against interleukin-17A. |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298102 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | Y4U029R8MS (ChemIDplus, GSRS) |
